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and Torben Lykke Sørensen1Abstract
Background: Dysregulation of the CCR3/CCL11 pathway has been implicated in the pathogenesis of choroidal
neovascularisation, a common feature of late age-related macular degeneration (AMD). The aim of this study was to
investigate the expression of CCR3 and its ligand CCL11 in peripheral blood in patients with neovascular AMD.
Methods: Patients with neovascular AMD and healthy controls were included. Blood samples were obtained and
prepared for flow cytometry to investigate the expression of CCR3. Levels of CCL11 were measured in plasma using
Cytometric Bead Array. Differences between the groups were tested using Kruskal-Wallis test and Mann–Whitney U
test.
Results: Patients (n = 83) with neovascular AMD and healthy control persons (n = 114) were included in the study.
No significant difference in the expression of CCR3 was found on CD9+ granulocytes when comparing patients
suffering from neovascular AMD with any of the control groups. We did not find any alteration in CCL11 levels in
patients among the age matched groups. There was no correlation between expression of CCR3/CCL11 and clinical
response to treatment with anti-vascular endothelial growth factor (VEGF).
Conclusion: Our results do not suggest a systemic alteration of the CCR3/CCL11 receptor/ligand complex in
patients with neovascular AMD.
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Age-related macular degeneration (AMD) is the leading
cause of blindness among elderly people in the devel-
oped part of the world [1]. The late stage of AMD pre-
sents in two distinct forms: Geographic atrophy (GA)
and neovascular AMD [2]. The introduction of anti-
vascular endothelial growth factor (VEGF) treatment has
drastically improved the course of neovascular AMD, but
the need for developing improved therapies is still
warranted [3].
The growth of a choroidal neovascularisation (CNV) is
probably mainly driven by VEGF, but clinical studies and* Correspondence: mailtilmads@gmail.com
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molecules, including chemokines, could be involved in
CNV growth [4-7]. In particular there has been a grow-
ing body of evidence suggesting an involvement of the
chemokine receptor CCR3 in CNV development [4,5,8].
Chemokines are released from sites of inflammation to
recruit cells that express chemokine receptors [9]. The
chemotactic function was previously believed to be the
main function of chemokines, but in the recent years
several other functions of the different chemokines and
chemokine receptors have been proposed. CCR3 is a G
protein coupled chemokine receptor. It is expressed
mainly on CD9+ eosinophil granulocytes and basophil
granulocytes, but also on Th2-cells. CCR3 is known for
its role in allergic diseases like allergic asthma, allergic
rhinitis, atopic dermatitis and may function by recruiting. This is an Open Access article distributed under the terms of the Creative
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CCR3 is also found on human endothelial cells [8].
In AMD, Takeda et al. [4] found that CCR3 was
expressed in choroidal endothelial cells, only in patients
with CNV, and in the same report laser-induced CNV
formation in mice was blocked with anti-CCR3 treatment.
In addition CCR3 expressing cells have been demon-
strated in post-mortem eyes from patients with neovascu-
lar AMD. In an experimental study of human choroidal
endothelial cells Wang et al. found that CCR3 expression
was increased in aging eyes [5]. Furthermore this study re-
ported that CCR3, when activated by the ligand CCL11,
increased migration of choroidal endothelial cells, whereas
it was inhibited by a CCR3 inhibitor [5]. In a recent study
Sharma et al. showed a significant association between
AMD and a single nucleotide polymorphism (SNP) in the
CCR3 gene [11].
CCR3 binds a variety of C-C chemokines one of which
is CCL11 (formerly known as eotaxin). CCL11 is best
known for its ability to mediate allergic responses and for
its ability to attract eosinophil granulocytes [12], however
several studies in mice have elucidated other potential
roles for CLL11, since an age dependant increase in circu-
lating CCL11 has been shown [13,14]. Importantly Salcedo
et al. reported some years back that CCL11 is involved
in angiogenesis [8]. In one study on circulating CCL24/
eotaxin 2, another ligand for CCR3, Sharma et al. found
an increased level of circulating eotaxin 2 in peripheral
blood in patients with AMD compared to controls [15].
We have previously found altered expression on per-
ipheral blood leukocytes in patients with AMD, among
others an increased expression of CD200 on peripheral
blood monocytes in patients with neovascular AMD [16].
Since CCR3 has been so strongly implicated in CNV
formation, it could be a target for treatment. However the
correlation between CNV and CCR3 has mainly been
shown in murine models of CNV. Therefore, we studied
the expression of CCR3 on CD9+ granulocytes and CD4+
T-cells in peripheral blood of patients with different clin-
ical stages of AMD, and measured the plasma levels of the
CCR3 ligand CCL11. This is the first study to investigate
the association between the peripheral CCR3/CCL11
receptor/ligand complex and AMD.
Methods
Participants
Patients with neovascular AMD attending our department
were asked to participate in this case–control study.
Patients attending our department for other reasons
were included as control subjects and divided in two
groups according to age: one group containing persons
70 years or older and one group containing persons
less than 70 years old. Patients were excluded from the
study if they had been diagnosed with autoimmune ormalignant disease, and patients were also excluded if
they were receiving immune modulating therapy. To
avoid interference with other acute-phase responses
due to infections, or to avoid interference with potentially
undiagnosed cancer, we excluded post hoc any participant
with a C-reactive protein (CRP) above 10 mg/L.
All participants underwent a structured interview aim-
ing at investigating previously and current medical condi-
tions and medication status. Smoking habits and alcohol
consumption were recorded. Patients were defined as
current smokers, former smokers (more than 100 ciga-
rettes during their lifetime) or never smokers. Alcohol
consumption was recorded and graded according to the
Danish National Board of Health’s recommendations
(maximum 7 units and 14 units per week for women
and men, respectively). Height and weight was mea-
sured to calculate the body mass index (BMI).
Verbal and written informed consent was obtained
from all participants prior to inclusion in the study. The
study has been approved by the Regional Committee of
Ethics in Research of the Region of Zealand (SJ-142)
and was performed in adherence to the Declaration of
Helsinki.
Ophthalmic examination
All patients included were examined with slit-lamp bio-
microscopy and fundoscopy, Spectral-Domain-Optical
Coherence Tomography (SD-OCT) (Spectralis HRA-OCT,
Heidelberg Engineering, Heidelberg, Germany), and
Fundus Autofluorescense Imaging. For exact diagnosis
fluorescein- and indocyanine green (ICG) angiography
(FA/ICG) was performed on all patients suspicious of
neovascular AMD. Visual acuity (VA) was measured
using the Early Treatment Diabetic Retinopathy Study
(ETDRS) chart.
Leukocyte preparation and flow cytometry
Venous blood samples were collected for flow cytometry
and CCL11 quantification from all patients prior to angi-
ography to avoid possible interference [17]. The blood
samples were prepared within 4 hours of phlebotomy for
flow cytometry by the following steps. Red blood cell
lysis was performed by adding 10% red blood cell lysis
buffer (Nordic Biosite 3AB, Täby, Sweden) to the whole
blood for 10 minutes at room temperature. After red
blood cell lysis the sample was washed three times in
isotonic buffer (IsoFlowTM Sheath Fluid Beckman
Coulter, Brea, CA, USA) and centrifuged for five mi-
nutes at 500G. After washing, the cells were incubated
at room temperature in the dark for 25 minutes with the
following monoclonal anti-human antibodies: CD9 (IgG1,
Clone: ALB6, Beckman Coulter, Brea, CA, USA), CD4
(IgG1, clone: 13B8.2 Beckman Coulter, Brea, CA, USA) and
CCR3 (IgG2a, clone: 61828, R&D Systems, Minneapolis,
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used and set at 1%. Flow cytometry was performed on a
Beckman Coulter FC 500 (Beckman Coulter, Brea, CA,
USA) flow cytometer.
The gating strategy for CD9 positive CCR3 positive
cells can be seen in Figure 1.
CCL11 quantification
Blood samples were centrifuged for 15 minutes at 1000 G,
and plasma was isolated and stored at −80 degrees Celsius
until analysis were performed. CCL11 was measured using
a Cytometric Bead Array (BD biosciences, Franklin Lakes,
NJ, USA) following the manufactures recommendations.
Clinical response
To assess the clinical relevance of peripheral expression
of CCR3 and CCL11 we looked at treatment response
after the initial three injections with Ranibizumab
(Lucentis®, Genetech, San Francisco, USA), since it has
been published that VA at this point of treatment is a
strong predictor of long term treatment response [18].
Patients in active treatment with Ranibizumab were di-
vided in groups according to their change in VA from
the first visit to the follow up visit. The patients were
first divided in three groups according to a change in VA
of 10 ETDRS letters or more, and secondly according to a
change in VA of 15 ETDRS letters or more.
Statistical analysis
The statistical software SPSS® version 19 for Windows
(IBM, Chicago, IL USA) was used for statistical analysis.
Kruskal-Wallis test and Mann–Whitney U test were used
for not normally distributed continuous variables (CCR3,Figure 1 The CCR3 expression was measured using flow cytometry. T
granulocytes and their expression of CCR3. A, Granulocytes were identified
then gated based on the CD9 expression. C, the fraction of CCR3+ cells wi
the percentage of CD9 positive granulocytes positive for CCR3 (Light grey)CCL11, age, BMI) and data are given as medians and
interquartile ranges (IQR). Categorical variables were ana-
lyzed using Pearson Chi-square test (Gender, alcohol-
intake, smoking habits). Correlation between variables
was tested using Spearman correlation test. A p-level of
less than 0.05 was considered significant.
Results
The chemokine receptor CCR3 was measured in 159
patients and the chemokine CCL11 was measured in
197 patients. The demographic and clinical data can be
seen in Tables 1 and 2. There was no significant difference
in male/female ratio, smoking habits, alcohol consump-
tion, or BMI between the groups. There was a significant
difference in age between the groups. This difference
disappeared when the group of young control persons
was excluded.
No significant change in percentage CD9 positive
granulocytes expressing CCR3 was found when compar-
ing the group with neovascular AMD with any of the
control groups (Figure 2 and Table 1). No correlation
was found when comparing the expression of CCR3 on
CD9 positive cells with smoking habits, BMI or physical
activity. No difference in expression of CCR3 on CD4
positive cells was found among the groups (data not
shown).
Table 2 and Figure 3 shows the plasma levels of
CCL11. There was an expected age related difference
in the plasma level of CCL11 between the group of
young control persons and the group of old control
persons (P = 0.035). Furthermore, we found a signifi-
cant increase in the CCL11 level in patients with neo-
vascular AMD (p = 0.001) when comparing this grouphe figure shows the gating strategy and quantification of CD9 positive
based on CD45 expression and side scatter. B, the granulocytes were
thin the CD9+ granulocyte gate was calculated. Histogram showing
and the negative isotype control set at 1% (dark grey).
Table 1 Demographic data and clinical characteristics of patients included in the study
nAMD
(n = 77)
Controls > 70 years
(n = 18)
Controls < 70 years
(n = 64)
P-value Test
Median Age in Years (min-max) 75.2 (60–92) 77.0 (70–89) 55.6 (32–69) 0.0001 Kruskal-Wallis test
Male % 36 39 42 0.702 Pearson
Chi-square test
Female % 64 61 58
Smoking habits:
Current smokers, (% yes) 19 12 19 0.956 Pearson
Chi-square test
Former smokers (% yes) 48 44 44
Never smokers (% yes) 33 44 37
Alcohol intake
Above recommended (% yes) 16 17 13 0.159 Pearson
Chi-square test
BMI (median, IQR), kg/m2 24.4 (22.7;28.6) 26.1 (24.1;29.3) 24.9 (22.0;29.7) 0.506 Kruskal-Wallis test
Percentage of CD9 positive granulocytes
expressing CCR3. (Median, IQR)
5.25 (2.8;9.1) 3.8 (2.0;6.4) 5.8 (2.6-5.8) 0.234 Kruskal-Wallis test
The table shows Demographic data and clinical characteristics of patients in whom CCR3 expression was measured. Difference among groups is calculated using
Kruskal-Wallis test and Pearson Chi square test. P-values are given.
AMD Age-related Macular Degeneration, nAMD neovascular AMD, IQR Inter Quartile Range, BMI Body Mass Index.
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was found when the group of patients with AMD was
compared with the age matched control group.
To assess the clinical relevance of the peripheral plasma
concentration of CCL11 level of CCR3 expression we
checked the change in VA after the three initial injections
with Ranibizumab. We divided the patients with AMD in
groups according to a change in VA as described previ-
ously. Table 3 shows the plasma levels of CCL11 and the
percentage of CD9 positive granulocytes expressing CCR3
among the different groups. We did not find any signifi-
cant difference in plasma level of CCL11 or expression of
CCR3 among the three groups when looking at a VATable 2 Demographic data and clinical characteristics of patie
nAMD (n = 83) Controls > 70 years (n =
Median Age in Years (min-max) 76.0 (63–92) 76.0 (70–85)
Male % 45 38
Female % 55 62
Smoking habits:
Current smokers, (% yes) 24 13
Former smokers (% yes) 40 33
Never smokers (% yes) 34 50
Alcohol intake
Above recommended (% yes) 17 14
BMI (median, IQR), kg/m2 25.5 (23.0;28.3) 26.1 (22.3;27.9)
Plasma concentration
of CCL11 (median, IQR) pg/ml
516 (342;721) 418 (275;840)
The table shows Demographic data and clinical characteristics of patients in whom
calculated using Kruskal-Wallis test and Pearson Chi square test. P-values are given.
AMD Age-related Macular Degeneration, nAMD neovascular AMD, IQR Inter Quartilechange of minimum 10 ETDRS letters . We also looked at
clinical meaningful change in VA defined as a change in
VA of at least 15 ETDRS and did not find any statistical
significant difference among the groups.
Discussion
The pathogenesis of AMD remains largely unknown.
Different pathogenic mechanisms have been suggested
in development of AMD. Formation of CNV is the hall-
mark of late stage neovascular AMD. It is generally ac-
cepted that CNV formation is mainly driven by VEGF but
other factors have proven to be involved in the formation
of CNV [19].nts included in the study
24) Controls < 70 years (n = 90) P-value Test
53.0 (30–69) 0.001 Kruskal-Wallis test
37 0.260 Pearson Chi-square test
63
14 0.650 Pearson Chi-square test
41
43
13 0.646 Pearson Chi-square test
24.5 (21.9;28.5) 0.757 Kruskal-Wallis test
361 (240;503) 0.001 Kruskal-Wallis test
plasma concentration of CCL11 was measured. Difference among groups is
Range, BMI Body Mass Index.
Figure 2 Percentage of CD9+ cells expressing CCR3 in young
controls (< 70 years), aged controls (>70 years) and patients
with neovascular AMD. Each dot represents one patient. The lines
denote medians and interquartile ranges (IQR). No significant
difference was found between the groups.
Figure 3 Plasma concentrations of CCL11 in young controls
(< 70 years), aged controls (>70 years) and patients with
neovascular AMD. Each dot represents one patient. The lines denote
medians and interquartile ranges (IQR). Significant differences between
groups are marked with p-values, Mann–Whitney U Test.
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have shown to be involved in angiogenesis. One mechan-
ism of involvement could be through Tryptase-chymase
double-positive human mast cells expressing CCR3 [20].
In an experimental study on human endothelial cells
Salceda et al. found that cells expressing CCR3 induced
an angiogenic response when exposed to the ligand CCL11
[8]. Several studies have suggested the involvement of
CCR3 and its ligands in the development of AMD and
CNV [4,5,21]. Different murine models of CNV have
formed a part of the investigation of the role of CCR3 in
CNV formation. Most of these studies point in the same
direction that CCR3 plays a role in the development of
CNV [4,5,21]. Ahmed et al. used a murine model to
study the role of Notch signalling in ocular angiogen-
esis. They found an increase in transcription level of the
pro-angiogenic factor VEGFR2 and CCR3 in subjects
with CNV compared to controls [22]. However Li et al.
investigated the CCR3 in relation to CNV also in a murine
model of CNV and found no evidence of the involvement
of CCR3 in CNV formation; in fact they could not find
any specific expression of CCR3 in or near the CNV [23].One reason for this could be that the mouse model used
in this study did not exert oxidative stress on the retinal
pigment epithelium (RPE) as suggested by Wang et al. In
an experimental study of human choroidal endothelial
cells Wang et al. found that CCR3 was only expressed in
the choroidal endothelial cells under certain conditions
such as increased age and oxidative stress. Oxidative stress
is a well known factor in the development of AMD and
CNV and Wang et al. showed that when the retinal sec-
tions were exposed to oxidative stress the response was an
increased expression of CCR3 in the choroidal endothelial
cells. Furthermore when these cells were stimulated with
CCL11 it induced a choroidal endothelial cell migration
[5]. Overall there is increasing evidence for the involve-
ment and importance of CCR3 in CNV formation when
expressed locally on the endothelial cells in the choroid.
Evidence points toward an increased level of CCR3 ex-
pression on choroidal endothelial cells in patients with
neovascular AMD. We hypothesized that the peripheral
expression of CCR3 would reflect the local CCR3 expres-
sion in the choroid. We studied the expression of CCR3
on peripherally CD9 positive eosinophiles and CD4 posi-
tive t-cells in patients with neovascular AMD and healthy
control persons. We did not find any difference in expres-
sion of CCR3 between the AMD-group and the control
groups. It is well known that chemokines and chemokine
receptors have diverse function locally and systemically.
Table 3 Plasma level of CCL11 or expression of CCR3 according to change in visual acuity
Gain of minimum 10 ETDRS
letters (n = 10)
VA change of less than 10 ETDRS
letters (n = 56)
Loss of minimum 10 ETDRS





473.6 (408.9;580.7) 534.1 (323.0;710.6) 427.7 (243.7;762.5) 0.725
CCR3 positive granulocytes
Median (IQR)
4.85 (3.18;6.08) 5.50 (4.13;9.67) 7.30 (3.18;10.7) 0.530
Gain of minimum 15 ETDRS
letters (n = 7)
VA change of less than 15 ETDRS
letters (n = 64)
Loss of minimum 15 ETDRS
letters (n = 11)
CCL11 plasma level
Median (IQR)
432,3 (390.5;635.8) 541.2 (351.4;699.5) 349.2 (240.7;667.1) 0.382
CCR3 positive granulocytes
Median (IQR)
4.60 (2.65;6.90) 5.50 (4.13;9.67) 8.00 (3.65;10.60) 0.496
The table shows the plasma level of CCL11 and expression of CCR3 among patients with neovascular AMD in active treatment with anti-VEGF. The clinical
relevance of CCL11 and CCR3 was tested by dividing the patients in groups according to change in visual acuity (VA). First we tested by dividing the patients in
three groups according to a change in VA of minimum 10 ETDRS letters and secondly by dividing the patients in three groups according to a VA change of
minimum 15 ETDRS letters. Difference among groups is calculated using Kruskal-Wallis test. P-values are given.
IQR Inter Quartile Range, BMI Body Mass Index, ETDRS Early Treatment Diabetic Retinopathy Study.
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cessarily reflected systemically. Since increasing evidence
points towards CCR3 as an important factor in developing
CNV our finding does not rule out the possible involve-
ment of CCR3 and it ligand CCL11 in CNV formation.
Our results show that the peripheral CCR3 expression
level is not altered in patients with neovascular AMD
compared to controls. However, the study is limited by its
relatively small number of patients included and its insti-
tutional study design. Furthermore, we have not measured
the CNV size prior to treatment. It is well known that
treatment response is related to CNV size. Most of the
studies that have investigated the role of CCR3 in CNV
formation have been experimental studies or studies on
murine models of CNV. Our study differs from the other
studies being an observational study on patients from a
clinical setting.
Wang et al. found evidence that there might be cross-
talk between CCR3 and VEGF. The study showed that
treating choroidal endothelial cells with CCL11 activated
VEGFR2 - the receptor for VEGF [5]. This is in line with
findings from several other studies where blockade of
CCR3 led to suppression of CNV formation [4,21]. In a
recent study Sharma et al. showed a significant associ-
ation between AMD and increased plasma level of
eotaxin 2/CCL24, however the control group was sig-
nificantly younger than the AMD group. The difference
in CCL24 described by Sharma et al. might be due to
the control group being 12 years younger than the
AMD group, since there is evidence that plasma level of
CCL11 changes with age [11].
We observed an age dependent increase in plasma
concentration of CCL11 which is in concordance with
findings in other studies [24,25]. We found a significant
increase in plasma CCL11 levels in patients with neovas-
cular AMD compared to young control persons, but did
not find any difference in CCL11 plasma concentrationwhen comparing the group of patients with neovascular
AMD with the age matched control group. This is in
contrast to the findings by Mo et al. who proposed
CCL11 as a possible biomarker for AMD. In a study in-
cluding 60 AMD patients and 20 controls they found
the plasma level of CCL11 increased in all stages of
AMD except neovascular AMD [25].Conclusion
CCR3 and its ligand CCL11 have been shown to play a
potential role locally in the eye in the development of
CNV. This is the first study to investigate the association
between the peripheral expression of CCR3 and concen-
tration of CCL11 and AMD. We did not find alterations
in CCR3/CCL11 expression in peripheral blood in patients
with neovascular AMD suggesting that the peripheral
expression of the CCR3/CCL11 receptor/ligand com-
plex plays a limited role in CNV formation in humans.
When looking at Ranibizumab treatment response in
terms of change in VA we found no significant correl-
ation with CCR3 and CCL11 expression. However it is
well known that chemokines and chemokine receptors
have diverse function systemically and locally and our
findings do therefore not rule out a potential role of
CCL11 and CCR3 expression in the choroid in the for-
mation of CNV.Abbreviations
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